Alto Neuroscience, Inc. Accumulated Other Comprehensive Income
Alto Neuroscience, Inc. (ANRO) had Accumulated Other Comprehensive Income of $17.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $17.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $13.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $22.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $14.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $17.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $22.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $14.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $31.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $14.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$101.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$95.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$89.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$84.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$79.00K 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |